Kazia Therapeutics Limited Board of Directors
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Ms. Gabrielle Heaton BBUS (ACC), CPA
Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer
Leaving Board of Directors Review
Your about to visit the following url
Invalid URL
Loading...
Comments
Comment created.